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Abstract
Chronic bacterial infection increased the risk of many solid malignancies and the underlying mechanism is usually ascribed to
bacterial-caused inflammation. However, the direct interaction of infectious bacteria with cancer cells has been largely overlooked.
We identified that highly metastatic breast cancer MDA-MB-231 cells expressed high level of Toll-like receptor 2 (TLR2) in contrast
to poorly metastatic breast cancer cells and homogenous untransformed breast cells. TLR2 in MDA-MB-231 cells were actively
triggered by peptidoglycan (PGN) from infectious bacterium Staphylococcus aureus (PGN-SA), resulting in the promoted
invasiveness and adhesiveness of the cancer cells in vitro. PGN-SA induced phosphorylation of TAK1 and IkBi nt h eT L R 2 - N F - kB
pathway of the cancer cells and stimulated IL-6 and TGF-bsecretion in MDA-MB-231 cells. All these effects were abrogated by TLR2
blockade. Further investigation showed that the NF-kB, STAT3 and Smad3 activities were augmented sequentially in MDA-MB-231
cells after PGN-SA stimulation. Phosphorylation of NF-kBp65 was initially increased and then followed by phosphorylation of
STAT3 and Smad3 in the delayed 4 or 6 hours. NF-kB inhibition attenuated STAT3 and Smad3 activities whereas PGN-SA-
stimulated cell culture supernatants reversed these inhibitory effects. Our study indicated that TLR2 activation by infectious
bacterial PGN played an important role in breast cancer cell invasiveness and illustrated a new link between infectious bacteria and
the cancer cells, suggesting the importance of antibiotic therapy to treat cancer with bacterial infection.
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Introduction
Metastasis seriously affects the survival of individuals with breast
cancer[1]. Bacterial infection mastitis may aggravate this malig-
nant metastasis [2,3]. It is necessary to investigate the molecular
mechanisms of breast cancer cell invasiveness and adhesiveness
under the conditions of bacteria infection. Solid evidences have
demonstrated that the underlying mechanism of chronic infection-
associated tumorigenesis is definitively ascribed to pathogen-
caused inflammation[4,5]. For an example, in gastric cancer,
Helicobacter pylori (H.pylori) plays a well-known risk factor of
tumorigenesis duo to H.pylori-caused chronic inflammation[4,6].
However, there were several reports showing that bacteria
component lipopolysaccharide (LPS) could directly promote
mouse colon tumor cell invasion and listeria monocytogenes could
promote mouse hepatic tumor growth by interaction of pathogens
directly with Toll-like receptors (TLRs) of tumor cells, despite
mediation of pathogen-caused inflammatory microenviroment
with infiltrating lymphocytes[7,8]. Nevertheless, the interaction
of bacteria with human cancer cells in invasiveness and
adhesiveness remains unknown. We hypothesized that the effect
of infectious bacteria directly on cancer cells could facilitate
invasiveness and adhesiveness of the cancer cells.
Toll receptors were initially found in Drosophila as an important
protein family which plays roles in dorso-ventral establishment of
developing embryo and Pathogene-Associated Molecular Patterns
(PAMPs) recognization for preventing fungal infection[9,10].
Subsequently, mammalian homologues of Toll receptors, now
termed Toll-Like Receptors (TLRs), were identified in immune
cells as pattern-recognition receptors (PRRs) responsible for the
detection of PAMPs in pathogene, and thus initiated innate
immunity[9]. The TLR family in mammal consists of 11 members
and each member recognizes different PAMPs of infectious
microbial components[10]. For examples, TLR2 recognizes
PAMPs in bacterial cellwall including bacterial lipopolysaccharide
and peptidoglycan (PGN); TLR9 senses the PAMP of microbial
plasmid, known as unmethylated DNA; TLR3 distinguishes the
RNA of virus[11]. Recent studies identified several TLRs in non-
immune system cells frequently involved in pathogenesis: TLR2 in
mesenchymal stem cells playing a role in the control of cell
differentiation[12]; TLR4 in adipocytes relating to insulin
resistance[13]; TLR4 in hepatic stellate cells enhancing TGF-b
signaling and hepatic fibrosis[14].
More recently, studies show several mouse and human tumor
cells express certain TLR members and the TLR activation by
bacteria or bacterial component seemed to promote tumor
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Listeria monocytogenes promoted mouse hepatic tumor and human
gastric carcinoma growth[8]; TLR9 activation by microbial
unmethylated oligodeoxynucleotide (CpG-ODN) induced MDA-
MB-231 cell invasion[16]. However, activation of TLR3 on human
hepatic cancer cells directly induced their apoptosis[17]; Activation
of rat prostate tumor cell TLR4 by Ecoli LPS inhibited tumor
growth[18]. In present study, we found that breast cancer cells of
different metastatic abilities expressed differential levels of TLR2
positively relating to cellular invasiveness and adhesiveness. The
peptidoglycan of Staphylococcus aureus (PGN-SA) triggered breast
cancer cell TLR2 with NF-kB, STAT3 and Smad3 activation
contributing to the cancer cell invasiveness and adhesiveness. Our
study illustrated a new TLR2-mediated pathway which disclosed
the effects of bacterial component on breast cancer cell independent
on infection-associated inflammation.
Methods
Reagents and antibodies
Matrigel and fibronectin were purchased form Becton Dick-
incon Biosciences (San Jose, CA, USA). PGN-SA (one of TLR2
ligands, peptidoglycan from Staphylococcus aureus), PGN-EB (one of
TLR2 ligands, peptidoglycan from Ecoli 0111:B4 strain), LPS-EB
(one of TLR4 ligands, lipopolysaccharide from Ecoli 0111:B4) and
neutralizing monoclonal antibody to human TLR2 were pur-
chased from Invivogen (San Diego, CA, USA). FITC-conjugated
primary anti-TLR2 monoclonal antibody and its isotype antibody
FITC-IgG2a were all purchased from eBiosciense Inc (San Diego,
CA, USA). SN50, a cell-permeable NF-kB inhibition peptide, was
purchased from Calbiochem (EMD Biosciences, Inc. San Diego,
CA, USA). Monoclonal anti-pNF-kB p65-S536 antibody and anti-
pSmad3-S423/425 antibody were purchased form Cell Signaling
Technology, Inc. (Danvers, MA, USA). PE-conjugated anti-
pSTAT3-Y705 antibody was obtained from Becton Dickincon
Biosciences (San Jose, CA, USA). FITC-conjugated secondary
antibody of goat anti-rabbit IgG (H+L) was purchased from
BioLegend (San Diego, CA, USA). Rabbit IgG, mouse IgG and
PE-conjugated primary mouse antibody IgG2a were obtained
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
Cell lines and cell culture
Human breast adenocarcinoma cell line MCF-7 (ATCC, NO
HTB-22), MDA-MB-468 (ATCC, NO HTB-22), MDA-MB-
231(ATCC, NO HTB-26) and nontransformed breast cell MCF-
10A(ATCC, NO HTB-26) were purchased from American Type
Culture Collection (ATCC; Rockville, MD, USA). These cell lines
were All cultured in Dulbecco’s modified Eagle’s high glucose
Medium supplemented with 10% FBS (Hyclone). The medium
was replaced every 2 days and once 80% confluent layer was
formed, the cells were removed using trypsin (0.05% EDTA,
0.25% trypsin; Sigma) and reseeded.
Evaluation of TLR2 expression
Flow cytometry (MOFLO, DAKO, Inc. CO, USA) was used to
quantify TLR2 expression. The two cell lines were separately
stained with FITC-conjugated TLR2 antibody or isotype IgG
according to the manufacturer’s instructions. Cells were analyzed
with a MoFlo flow cytometer and the data were analyzed by
Summit Software v4.3 (DAKO, Inc. CO, USA).
Real time-PCR to analyze the expression of TLR2 mRNA
Total RNA was extracted by a single-step method with TRIzol
reagent (Invitrogen Corp., Carlsbad, CA, USA). For measuring
RNA concentration and protein contamination, absorbance of
RNA solution was measured at OD 260 and 280 nm. The reverse
transcriptase reaction was carried out using avian myeloblastosis
virus (AMV) reverse transcriptase (Promega, Madison, WI, USA).
PCRs were performed according to the real time PCR machine
manufacturer’s instructions (ABI 7300), which allow real time
quantitative detection of the PCR product by measuring the
increase in SYBR green fluorescence caused by binding of SYBR
green to double-stranded DNA. The SYBR kit for PCRs was
purchased from PerkinElmer Life Sciences. TLR2 mRNA yield
differences were calculated using GAPDH as endogenous control
and the comparative threshold cycle (Ct value)[19]. Primers for
human TLR2 and b-actin were designed were designed according
to I. Kokkinopoulos[20].
Transwell invasion assay
The bottoms of the inner transwells (8.0 mm pore size, 6.5 mm
diameter; Corning Costar, Inc. CA, USA) were coated with
paraffin to avoid meniscus formation. Then, the bottoms of the
transwells were coated with a thin layer of matrigel (2.5 mg/ml).
The two cell lines in DMEM containing 0.2% BSA were seeded
on top of this matrigel at a quantity of 50,000 cells per chamber.
The cells were cultured in serum-free medium in the inner
compartment inside the transwell. To the outer compartment
outside the transwell, we added 600 ml DMEM with 10% FBS.
After 24 h culture, the cells were fixed with 2% paraformaldehyde
in 16PBS and stained with 0.05% toluidine blue in 2% Na2CO3/
water solution. After wiping off the inside of the chambers using
cotton-tipped applicators, invasive cells remained on the bottom of
the membranes and were counted under the microscope
(magnification, 6200)[21].
In vitro adhesion to fibronectin assay
Twenty-four-well culture dishes were pre-coated with 80 mlo f
Fibronectin (2.5 mg/ml) adhesion buffer (0.25% BSA in HBSS)
for 30 min at 37uC. 1610
5 cancer cells were added to each well.
After 30 min at 37uC in a CO2 incubator, nonadherent cells were
removed by gentle wash with HBSS. Then, the cells were fixed
with 2% paraformaldehyde in 16PBS and stained with 0.05%
toluidine blue in 2% Na2CO3 water solution. The adherent cells of
the bottom were counted under the microscope (magnification,
6100).
ELISA
1610
5 cancer cells were cultured in 24-well plates for 24 h and
the supernatants were assayed for IL-6, TGF-b, VEGF and
MMP9 using an ELISA kit (R&D Systems, Minneapolis, MN,
USA) according to the manufacturer’s instructions.
Western-blotting
For pTAK1 or pIkBa detection, the cells were resuspended in
lysis buffer (10 mM Tris–HCl, pH 8.0, 137 mM NaCl, 10%
glycerol, 1% Triton X-100, 1 mM Na3VO4, 1 mM phenylmethyl-
sulfonyl fluoride, 10 mg/ml leupeptin, 1 mg/ml aprotinin). For
TLR2 detection, the cells were lysed in RIPA buffer (50 mM
HEPES, 150 mM NaCl, 1% deoxycholate, 1% NP-40, 0.5% SDS
and protease inhibitor). The cell lysates were centrifuged for
20 min at 16,000 g, and then equal amounts of protein (30 mg)
were separated by 10% SDS-PAGE, and transferred onto PVDF
membranes (Millipore, Bedford MA, USA). After blocking in non-
fat dried milk, membranes were probed with primary antibody in
a solution of PBS containing 0.1% Tween20. After three 10-min
wash in PBS/0.1% Tween20, blots were incubated with
Pathogen-Host Interactions
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reactive bands were detected using the enhanced chemilumines-
cence system (Amersham, Piscataway, NJ, USA).
Intracellular phospho-protein staining techniques for
flow cytometer analysis
Formaldehyde in 0.5–1 ml PBS was added to each cell sample,
to a final concentration of 2%, and cells were fixed for 10 min at
37uC. To make cells permeable, they were slowly added to ice-cold
100% methanol to a final concentration of 90%. Then, cells were
incubated for 30 min on ice. Two milliliters of 2% BSA blocking
buffer was added to each tube, and tubes were rinsed by
centrifugation at 350 g. The permeabilized cells were resuspended
in 100 ml blocking buffer and primary antibody was added to each
tube, which was incubated on ice for 45 min. After two wash in
blocking buffer to delete antibodies with non-specific attachment,
the cells were resuspended in FITC-conjugated secondary
antibody. After 30 min, cells were rinsed again and resuspended
in 0.5 ml PBS for analysis by MoFlo flow cytometer (DAKO, Inc.
CO, USA). The strength of fluorescence was measured by the
median fluorescence intensity (MFI). Fold change was calculated
by dividing the MFI of the treated sample (MFI treated) from that
of the control sample (MFI untreated), i.e., fold change percent
%=(MFI treated/MFI untreated) 6100[22].
Statistical analysis
The values were expressed as mean 6 SD. Statistical
comparison was made using Student’s t test, and the level of
significance was established at p,0.05 and p,0.01.
Results
TLR2 was differentially expressed in breast cancer cell
lines
Previous report pointed that mouse hepatoma H22 cells
expressed TLR2 receptor involved in tumor growth by listeria
monocytogenes stimulation[8]. We sought to determine the effect of
TLR2 stimulation with infectious bacteria on breast tumor
invasiveness and adhesiveness. Therefore, we initially detected
TLR2 expression levels of selected breast cancer cell lines. By flow
cytometer detection, we found TLR2 was differentially expressed
in MCF-10A, MCF-7, MDA-MB-468 and MDA-MB-231.
Qualitative PCR analysis indicated the similar result. TLR2
protein level in MDA-MB-231 cells was much higher than the
other cell lines (Fig. 1A and B). Real-time PCR analysis showed
the number of threshold cycles (Ct) of MDA-MB-231 was the least
among those of other three cell lines (Fig. 1C). These results were
confirmed by western blot analysis (Fig. 1D). Since each of these
cell lines is distinguished in invasive and metastatic capacities,
Figure 1. TLR2 was differentially expressed in breast cancer cells and untransformed breast cells. (A and B) Surface expression of TLR2 in
four cell lines was analyzed by direct immunofluorescence using flow cytometer and IgG was used as control antibodies. The differences of TLR2
expression levels in breast cancer MCF-7, MDA-MB-468 and MDA-MB-231 cells were significant and TLR2 in untransformed MCF-10A cells was nearly
undetectable. (C) TLR2 mRNA levels in the cell lines were measured by real-time PCR. RNA yield differences were calculated using GAPDH as an
endogenous control and the comparative threshold cycle (Ct value). MDA-MB-231 cells showed the lowest Ct value among these cell lines. (D) TLR2
protein levels were analyzed by Western-blotting. Values were expressed as mean 6 SD (n=6*p,0.05; **p,0.01).
doi:10.1371/journal.pone.0010850.g001
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to their metastatic capacity.
PGN-SA promoted breast cancer cell invasiveness and
adhesiveness via TLR2
Metastatic process involves several critical steps such as invasion
and adhesion[23]. To investigate the effects of TLR2 on the
metastatic process of the breast cancer cell lines, the Transwell
experiment for invasion assay was set up and only highly invasive
cells can invade through the matrigel layer and migrate through
the 8.0 mm holes[21]. Among the three breast cancer cell lines,
MDA-MB-231 cells showed highest capacity in invasion (Fig. 2A).
Utilizing TLR2 agonist PGN-SA (1 mg/ml) to activate TLR2 and
anti-TLR2 neutralizing antibody to block TLR2, we found that in
MDA-MB-231 cells, PGN-SA stimulation promoted more than 2-
fold invasive capacity than the unthreatment (Fig. 2A). On the
contrary, anti-TLR2 neutralizing antibody notably attenuated the
number of invasive breast cancer cells (Fig. 2A). Adhesion to
extracellular matrix (ECM) is an important capacity for cancer cell
to anchor on the matrix[23]. We deploy fibronectin, an important
component of ECM, to investigate the effect of TLR2 activation
on MDA-MB-231 cell adhesiveness to this kind matrix. PGN-SA
Figure 2. PGN-SA promoted invasiveness and adhesiveness via TLR2 in MDA-MB-231 cells. (A) The bottoms of the top cells in Transwell
setting were all coated with a thin layer of matrigel and only the cells with invasive capacity could migrate through the matrigel layer and 8.0 mm
pore. IgG (10 mg/ml) treatment was a antibodies control. TLR2 activation by PGN-SA (1 mg/ml) increased the invasive cell number of breast cancer cell
lines whereas TLR2 inhibition by anti-TLR2 neutralizing antibody (10 mg/ml) attenuated the invasive cells. (B) The culture dishes were pre-coated with
80 ml of fibronectin (2.5 mg/ml). The adhesive cancer cells stained with 0.05% toluidine blue solution. PGN-SA (1 mg/ml) enhanced MDA-MB-231 cell
adhesion to fibronectin layer whereas anti-TLR2 neutralizing antibody (10 mg/ml) abrogated PGN-stimulated adhesive ability. Values were expressed
as mean 6 SD and in vitro experiments, one representative of six independent is shown (n=6 *p,0.05; **p,0.01).
doi:10.1371/journal.pone.0010850.g002
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whereas there is no such a similar effect in MCF-7 cells by
PGN-SA stimulation (Fig. 2B).
TLR2 activation by PGN-SA-triggered NF-kB activity
NF-kB activition has been found in breast cancer cell lines and
plays a pivotal role in metastatic progress of breast cancer
cells[24,25]. In immune cells, TLR2 stimulation enhances NF-kB
activation[26]. We therefore investigated whether TLR2 activa-
tion in human breast cancer cells leads to NF-kB activity. By
PGN-SA stimulation, MDA-MB-231 cells up-regulated NF-kB
activity 4-fold stronger whereas TLR2 blockade by anti-TLR2
neutralizing antibody significantly decreased NF-kB activity
(Fig. 3A and B). PGN of Ecoli 0111:B4 (PGN-EB), another
TLR2 agonist, also increased NF-kB activity in MDA-MB-231
cells, but such a response of NF-kB activity was not caused by
LPS-EB (a TLR4 agonist) (Fig. 3A and B). Nevertheless, PGN-
SA and PGN-EB could not trigger NF-kB activity in poorly
metastatic and TLR2-low expressed MCF-7 cells (Fig. 3A and B).
These results indicated that highly metastatic breast cancer cell
MDA-MB-231 cells interacted with the bacterial PAMPs by TLR2
but not TLR4, and thus leaded to NF-kB to activation. The poorly
metastatic MCF-7 cells could not result in the similar effect. To
confirm the signal pathways of TLR2-NF-kB, we further
investigated pTAK1 and pIkBa, the two critical kinases in
TLR2-NF-kB signaling[26]. The result showed that after PGN-
SA stimulation, phosphorylation level of TAK1 and IkBa in
MDA-MB-231 cells were significantly increased but the parallel
test for MCF-7 cells did not appear significant increase
(Fig. 3C.D).
Figure 3. Bacterial component PGN-SA enhanced TLR2-NF-kB signaling in breast cancer cells. (A and B) Specific expression of the
phospho-NF-kBp65 was detected in cancer cells using flow cytometry assay, for which equal volume of PBS treatment served as a control. PGN-SA
(1 mg/ml) and PGN-EB (1 mg/ml) promoted augment of NF-kB activation in MDA-MB-231 cells nearly 4-fold more than MCF-7 cells. LPS-EB (1 mg/ml), a
TLR4 agonist, had no such an effect. TLR2 blockade by its neutralizing antibody (10 mg/ml) abrogated PGN-SA-stimulated NF-kB activities in both
MDA-MB-231 and MCF-7 cells. (C and D) PGN-SA increased amounts of phospho-TAK1 and phospho-IkBa in MDA-MB-231 cells in contrast to MCF-7
cells. Values were expressed as mean 6 SD and one representative of six independent experiments was shown (n=6 *p,0.05; **p,0.01; #p,0.05).
doi:10.1371/journal.pone.0010850.g003
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distinguished IL-6 and TGF-b secretion in invasive
MDA-MB-231 cells
The results above indicated that TLR2 activation by
bacterial PAMPs of PGN promoted breast cancer cell
invasiveness and adhesiveness as well as TLR2-NF-kB
signalling activation. Cancer cell NF-kB activation could lead
to abnormal cytokine transcription and thus regulate the
cancer cell biology in metastatic process[27,28,29]. For
example, NF-kB-mediated IL-6 promotes cancer cell prolifer-
ation and invasion[29]. We examined the cytokines secreted by
MDA-MB-231 cells in culture supernatants involving IL-6,
TGF-b, VEGF and MMP9 which are required for cancer
cellular invasion and metastasis[30,31,32,33]. Among the
cytokines we investigated, IL-6 and TGF-b increased up to
5-folds and 7-folds respectively after TLR2 stimulation with
PGN-SA (Fig. 4A and B). However, TLR2 blockade reduced
IL-6 and TGF-b (Fig. 4A and B). Although the PGN-SA-
induced increment of VEGF and MMP9 also appeared, the
secretion quantitative of these cytokines was not different
between MCF-7 and MDA-MB-231 cells (Fig. 4C and D).
Differentially, IL-6 and TGF-b secreted by MDA-MB-231 cells
under the condition of PGN-SA stimulation were up to 3-fold
higher than MCF-7 (Fig. 4A and B).
TLR2 activation triggers STAT3 and Smad3 activation
From the results above, the secretion of IL-6 and TGF-b in
MDA-MB-231 cells were in higher level than in MCF-7 cells. To
determine the consequence of the IL-6 and TGF-b increment, we
investigated the cytokine-coupled transcriptional factor signals of
STAT3 and Smad3 which were identified as important factors
responsible for malign tumor progress[34,35]. Phosphorylation
analysis by flow cytometer revealed that in MDA-MB-231 cells,
STAT3 and Smad3 activities were all enhanced by PGN-SA
stimulation whereas TLR2 blockade significantly attenuated
STAT3 and Smad3 activities (Fig. 5A–D). In stead, TLR2-low
MCF-7 cells did not show significantly variance in Smad3 and
STAT3 activation. In addition, blockade of TLR2 abrogated
PGN-SA-induced STAT3 and Smad3 activation.
TLR2 activation sequentially stimulates NF-kB, STAT3 and
Smad3 activation
Recent reports show that NF-kB activation is essential for
breast cancer metastasis due to their contribution to epithelial-
mesenchymal transition (EMT) and anti-apoptosis effect[24]. In
addition, STAT3 and Smad3 activations were also necessary to
the metastatic steps such as invasion and proliferation[34,35].
Our study above showed that PAMPs of bacterial peptidoglycan
triggered NF-kB, STAT3 and Smad3 activities via TLR2
Figure 4. TLR2 activation by PGN-SA increased IL-6, TGF-b, VEGF and MMP9 secretion. (A and B) Cancer cells were cultured for 24 hours
and the supernatants were analyzed by ELISA assay. MDA-MB-231 cells with PGN-SA (1 mg/ml) stimulation secreted IL-6 and TGF-b 4-folds more than
untreated cells whereas TLR2 blockade by its neutralizing antibody (10 mg/ml) reduced IL-6 and TGF-b secretion obviously. (C and D) PGN-SA
stimulation significantly up-regulated VEGF and MMP9 secretion in both MDA-MB-231 and MCF-7 cells. Blockade of TLR2 attenuated amounts of
VEGF and MMP9 in MDA-MB-231. (A, B, C and D) NF-kB cell-permeable inhibitor peptide SN50 (10 mg/ml) abrogated these cytokine increment by
PGN-SA stimulation. IgG (10 mg/ml) served as antibody control. Values were expressed as mean 6 SD (n=6 *P,0.05; **P,0.01;
#P,0.05;
##P,0.01).
doi:10.1371/journal.pone.0010850.g004
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factors responding to bacterial PAMPs, we analysed phosphor-
ylation levels of these transcriptional factors on arrange of time
points. On different time points, three transcriptional factors
showed sequential activation after receiving bacterial PAMPs
stimulation (Fig. 6A–D). On 30 min, phosphorylation of NF-kB
was firstly triggered up to maximum level by PGN-SA (Fig. 6A).
Then, after additional 4 h and 6 h, phosphorylation level of
STAT3 and Smad3 were sequentially induced to near peak
value (Fig. 6B and C). These results indicated that TLR2-
associated NF-kB, STAT3 and Smad3 activities depended
on a temporal manner mechanism, suggesting that NF-kB
activity was responsible for sequential STAT3 and Smad3
activation.
Figure 5. PGN-SA stimulation induced STAT3 and Smad3 activation via TLR2. (A, B, C and D) Phospho-STAT3 and Phospho-Smad3 were
detected in cancer cells using flow cytometry assay and equal volume of PBS treatment served as a control. STAT3 and Smad3 activation were all
enhanced by PGN-SA stimulation whereas TLR2 blockade hampered STAT3 and Smad3 activation. (C and D) On contrast to TLR2-low cell line MCF-7,
MDA-MB-231 cells showed more sensitive to PGN-SA stimulation. Values were expressed as mean 6 SD (n=6 *P,0.05; **P,0.01).
doi:10.1371/journal.pone.0010850.g005
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To determine whether STAT3 and Smad3 sequential activities
required NF-kB activation, we deployed a NF-kB inhibitor, cell-
permeable peptide SN50, to observe the consequence of NF-kB
inhibition. The results showed that SN50 significantly decreased
PGN-SA-induced STAT3 and Smad3 activities (Fig. 7A–C).
These results demonstrated that inhibition of NF-kB could
Figure 6. PGN-SA induced NF-kB, STAT3 and Smad3 activation sequentially in MDA-MB-231 cells. (A) The cancer cells were incubated
with PGN-SA on the indicated time points of 0 min, 10 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h. Anti-phospho-NF-kBp65, anti-Phospho-STAT3 and anti-
Phospho-Smad3 were respectively used to mark the special target in permeabilized MDA-MB-231 cells. On 30 min, NF-kB was firstly stimulated up to
maximum level. (B and C) After additional 4 h or 6 h, activations of STAT3 and Smad3 were respectively induced. Values were expressed as mean 6
SD (n=3 *P,0.05; **P,0.01).
doi:10.1371/journal.pone.0010850.g006
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NF-kB activity was required for augment of STAT3 and Smad3
activities by PGN-SA stimulation. Since PGN-SA stimulation
enhanced secretion of IL-6 and TGF-b in culture supernatant, we
used PGN-SA-stimulated cell culture supernatant to replace the
supernatant of PGN-SA+SN50 treated cells. Notably, we found
that PGN-SA-stimulated supernatant treatment reversed the
STAT3 and Smad3 activity regression by SN50 inhibition
(Fig. 7A–C). Combined with ELISA results above, these results
illustrated that PGN-SA-stimulated NF-kB in MDA-MB-231 cells
resulted in releasing IL-6 and TGF-b and thus promoted STAT3
and Smad3 activity whereas if NF-kB was inhibited, the IL-6 and
TGF-b as well as their coupled transcript factor STAT3 and
Smad3 activities were also deduced.
Figure 7. NF-kB activation is essential for STAT3 and Smad3 activation in breast cancer cells. (A, B and C) PGN-SA challenge increased the
levels of STAT3 and Smad3 activation whereas NF-kB inhibitor SN50 (10 mg/ml) abrogated these effects of PGN-SA stimulation. After the cells
incubated with PGN-SA for 6 h, PGN-SA-stimulated cell culture supernatant replaced the supernatant of PGN-SA+SN50 group and in this group (PGN-
SA+SN50+Surpnatant), the STAT3 and Smad3 activities were increased to the levels of PGN-SA treatment once more. Values were expressed as mean
6 SD (n=6 *P,0.05; **P,0.01).
doi:10.1371/journal.pone.0010850.g007
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In this study, we identified that TLR2 was differentially
expressed in breast epithelial cancer cell lines and homogenous
untransformed breast cell lines. TLR2 expression levels in these
cell lines were consistent with their differential metastastic
capacities. Toll-like receptors(TLRs) are sensitive to pathogene-
associated molecular patterns (PAMPs) and damage-associated
molecular patterns (DAMPs) released by pathogen and injured
tissue[36,37,38]. Recent accumulated studies show TLRs in the
cells of different tissue plays an important role in pathogenesis of
many diseases[14,37]. For example, TLR4 signaling in hepatic
stellate cells enhanced TGF-b secretion and hepatic fibrosis[14].
Moreover, tumor cells also expressed certain member of TLR
family leading to response to bacterial component. For examples,
Gram-positive bacterium Listeria monocytogene accelerated mouse
hepatocarcinoma cell H22 growth via TLR2 signaling[8]; TLR9
agonist CpG ODN promotes breast cancer cell MDA-MB-231 to
activation of invasion via increased MMP9 secretion[16]. Our
study shows that compared with nearly undetectable TLR2 level
in untransformed breast cells, classic highly metastatic breast
cancer MDA-MB-231 cells express high level of TLR2. Cancer
cell TLR2 activation by peptidoglycan of pathogenic bacterium
Staphylococcus aureus resulted in enhancement of invasiveness and
adhesiveness. However, TLR2 blockade abrogated such an effect.
As a pathogenic bacterium frequently contains both TLR2
agonist[11], our results indicated that breast cancer invasiveness
and adhesiveness would be enhanced after the stimulation by
peptidoglycan in bacteria and the highly metastatic breast cancer
cells are more sensitive to pathogenic bacterial peptidoglycan than
poorly metastatic breast cancer cells.
Bacterial infection or bacterial contamination following tumor
surgery has been shown to be a risk factor of tumor metastatic
recurrence, the underlying mechanisms is ascribed to infection-
induced inflammation[3,39,40,41]. Nevertheless, direct interac-
tion between bacteria and tumor cells has been largely overlooked.
In a murine model of metastasis, animals subjected to laparotomy
or air laparoscopy with high levels of Endotoxin/LPS contami-
nation had increased lung metastatic burden[7]. In the present
study, we provided new insight into the relationship between
bacteria infection and metastasis. Since the bacterial component
peptidoglycan directly stimulated breast cancer cells invasiveness
and adhesiveness via cancer cell TLR2 activation, our results
suggest breast cancer patient might be necessarily noticed
mastectomy or mastitis-caused bacterial infection, especially
induced by Gram-positive bacteria which usually enriched much
more peptidoglycan, and indicate the significance for bacterial
infection-associated cancer to receive antibiotic therapy. Since
common bacterial vaccine may contain TLR2 agonist, attention
should also be paid to the effects of bacterial vaccines for
immunotherapy on cancer cells. These require a design and
genetically modified strategy to develop bacterial vaccine with
reduced TLR2-activating potential.
We further report that PGN-SA elicited an augment of
constitutive NF-kB activity via activation of TLR2 in breast
cancer cells whereas TLR2 blockade or NF-kB activity inhibition
decreased these cytokine secretions. Solid evidence has verified
NF-kB as an essential factor in breast cancer metastasis[24,29].
Recent reports emphasized that strong constitutive NF-kB activity
in the highly invasive breast cancer MDA-MB-231 cell line
compared with several breast cancer cell lines that are poorly
invasive and metastatic[25]. However, the factors which induce
NF-kB different activities in invasive or non-invasive breast cancer
cells have not yet been elucidated. Our results indicated that PGN-
SA powerfully mediated NF-kB higher activation in invasive
MDA-MB-231 cells than in non-invasive MCF-7 cells due to
differential expression of TLR2. In addition, PGN-SA triggered
increase of pTAK1 and pIkBa which are two key kinases in the
TLR2-NF-kB signal pathway that exists in immunocells and
epithelial cells[26], and these results validated a TLR2-NF-kB
signaling in invasive MDA-MB-231 cells. Accumulated evidences
showed that the consequence of NF-kB signaling associated with
cytokine secretion and cytokines secreted by cancer cells exerted
an important effect on control of cancer cell biology such as
proliferation, EMT and invasion[42]. For examples, IL-6
promotes cancer cell proliferation and recent studies showed that
IL-6 also contributed to cancer cell malignant properties and
effusion respectively in lung and breast cancer[43,44]; TGF-b
induces cancer cell invasion and EMT in breast cancer[27,45];
VEGF and MMP9 are also regarded as indispensable cytokines for
breast cancer cell invasion, adhesion and metastasis[32,46]. We
indicated that PGN-SA challenged cancer cells produce more
amounts of these cytokines contributing MDA-MB-231 cells to be
more invasive and adhesive.
Among those cytokines we analyzed, TLR2-NF-kB activation
specially promoted IL-6 and TGF-b higher secretions in invasive
MDA-MB-231 cells rather than that in MCF-7 cells. We conclude
that IL-6 and TGF-b signal in TLR2-NF-kB-mediated mecha-
nism in MDA-MB-231 cells is very important. Here we further
found that PGN-SA effectively triggered STAT3 and Smad3
activation with which respectively were coupled by IL-6 and TGF-
b signal. NF-kB, STAT3 and Smad3 activities after PGN-SA
stimulation were not on the same time point. Phosphorylation of
NF-kB was firstly promoted up to maximum level on 30 min and
then phosphorylation of STAT3 and Smad3 were sequentially
induced to near maximum level at 4 h and 6 h. These finding
indicated that PGN-SA-stimulated TLR2 activation increased NF-
kB, STAT3 and Smad3 activities depending on a time pattern.
Moreover, TLR2-triggered STAT3 and Smad3 activities could be
suppressed by NF-kB inhibition which also decreased IL-6 and
TGF-b increments after TLR2 stimulation. Combining these
findings, we concluded that TLR2-NF-kB signaling in MDA-MB-
231 cells enhances cytokine production involving IL-6 and TGF-b
leading STAT3 and Smad3 to sequential activation, respectively.
The supernatant of PGN-SA+SN50 treated cells was replaced by
the cell culture supernatant with PGN-SA, which could reverse the
regression of STAT3 and Smad3 activities previously inhibited by
SN50. Thus, STAT3 and Smad3 sequential activities in the cancer
cells depended on IL-6 and TGF-b secreted in the supernatant
and required NF-kB activity. Collectively, we illustrated a TLR2-
mediated mechanism in metastatic breast cancer cell challenged
by PGN, a major surface component of Gram-positive bacteria.
TGF-b-Smad3 signaling acts as critical role in breast cancer cell
invasion and EMT[34]. IL-6 triggers malignant features in human
ductal breast carcinoma and IL-6-STAT3 signaling cascade is
important for epithelial tumorigenesis and dissemination[33,43].
Our findings indicate that PGN-stimulated TLR2 activation in
highly metastatic breast cancer MDA-MB-231 cells induced
extensive molecular activations involving three important tran-
scriptional factor activities which are essential for control of cancer
cell malignant properties[34,47,48].
Taken together, high level TLR2 expressed in metastatic
human breast cancer cells and mediated a bacterial component,
PGN, to stimulate NF-kB activity resulting in STAT3 and Smad3
sequential activation, which contributed to invasiveness and
adhesiveness. Our study reveals a direct relationship of cancer
cells with pathogenic bacteria, suggesting a TLR2-mediated
mechanism in bacterial infection-associated human breast cancer
Pathogen-Host Interactions
PLoS ONE | www.plosone.org 10 May 2010 | Volume 5 | Issue 5 | e10850metastasis. Since many cancer patients with weaken immune
systems appear to be susceptible to bacterial infection and surgical
contamination and there are always sporadic serious or light cases
of surgical infection in clinic every year[3,5,49], our findings
pointed importance of antibiotic therapy to treat breast tumor with
bacterial infection especially of Staphylococcus aureus, a notable drug-
resistant pathogen that easily occur in clinic. In addition, as some
bacterial vaccine and adjuvant used in cancer treatment usually
contain TLR2 agonist, this study is also relevant to genetic
strategy for bacterial vaccine and adjuvant design in cancer
immunotherapy.
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